Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Expanded Access
  • Colorado


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
    NCT02955446
    Conditions:   Neoplasm;   Desmoid Tumor
    Intervention:   Drug: PF-03084014
    Sponsors:   University of Colorado, Denver;   SpringWorks Therapeutics, Inc.
    No longer available
  • CTL019 Out of Specification MAP for ALL or DLBCL Patients
    NCT03601442
    Conditions:   Acute Lymphoblastic Leukemia (ALL);   Diffuse Large B-cell Lymphoma (DLBCL)
    Intervention:   Biological: CTL019
    Sponsor:   Novartis Pharmaceuticals
    Available
  • Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
    NCT03433131
    Conditions:   Narcolepsy Without Cataplexy;   Narcolepsy With Cataplexy
    Intervention:   Drug: Pitolisant
    Sponsor:   Harmony Biosciences, LLC
    No longer available
  • Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
    NCT02624570
    Conditions:   Acute Myeloid Leukemia (AML) With;   FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
    Intervention:   Drug: Midostaurin
    Sponsor:   Novartis Pharmaceuticals
    Available
  • This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
    NCT00244686
    Condition:   Hypereosinophilic Syndrome
    Intervention:   Drug: Mepolizumab
    Sponsor:   GlaxoSmithKline
    Available
  • A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
    NCT00149981
    Condition:   Organ Transplantation
    Intervention:   Drug: everolimus (RAD)
    Sponsor:   Novartis Pharmaceuticals
    No longer available
  • An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
    NCT03154437
    Condition:   Hemophilia A
    Intervention:   Biological: Emicizumab
    Sponsor:   Genentech, Inc.
    Approved for marketing
  • Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
    NCT02473497
    Condition:   Neoplasm
    Intervention:   Drug: Crizotinib
    Sponsor:   Pfizer
    Available
  • Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
    NCT02187354
    Condition:   Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
    Interventions:   Drug: Blinatumomab;   Other: Extension of LTFU as per ProtocolAmendment7 7Jun18
    Sponsor:   Amgen
    No longer available
  • Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
    NCT03070093
    Conditions:   Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
    Intervention:   Drug: gilteritinib
    Sponsor:   Astellas Pharma Global Development, Inc.
    Available

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC